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Long Noncoding RNAs: Chromatin modification in Cancer
Laura Rodríguez Muñoz. Degree in Biomedical Sciences, Autonomous University of Barcelona.
łLncRNAs exert a major role in gene regulation, for instance, through chromatin modification. Thus, its deregulation can
contribute to the development and progression of several diseases such as cancer.
łTaking advantage of their high tissue-specificty, lncRNAs could be used both as diagnostic and prognostic cancer
biomarkers. Indeed, lncRNA prostate cancer gene 3 (PCA3) is already used for prostate cancer detection.
łLncRNAs can be regarded as potential therapy targets in cancer: oncogenic lncRNAs could be assessed with RNA-
mediated gene silencing while loss of tumor-suppressor lncRNAs could be approached with gene therapy.
Introduction
LncRNAs
Role of lncRNAs in cancer
Conclusions
Definition. LncRNAs are endogenous cellular RNAs of more than 200 nucleotides that lack an 
open reading frame of significant length (DPLQRDFLGV
Genome research has been mainly focused on protein coding genes (PCGs).
 ł Advances in DNA sequencing and microarrays revealed a much more complex
transcriptional landscape raising dramatically the interest in noncoding RNAs.
ł MicroRNAs became the aim of exhaustive studies.
 ł Attention is now shifting towards long noncoding RNAs (lncRNAs).
ł Central regulators of gene expression involved in several diseases, including cancer.
 
Review the main characteristics of lncRNAs as gene regulators.
Describe the mechanism underlying chromatin modification by four different lncRNAs.
Highlight the links between lncRNAs deregulation and cancer.
Aims
Initial search in PubMed (NCBI) for scientific reviews publicated within the last 5 years containing
the keywords “long non-conding RNAs” OR “long noncoding RNAs” OR “lncRNAs” AND cancer.
Knowledge acquired upon reading these reviews allowed further searches in PubMed and Web of
Knowledge for original articles.
Materials and Methods
Classification. Generally according to their location with respect to PCGs:
Intergenic (lincRNAs) (Fig.1A), which do not intersect PCGs.
Genic, which are subclassified into:
ł Exonic transcripts (Fig.1B)-intersect an
exon of a PCG on the opposite strand.
ł Intronic transcripts (Fig. 1C)-lie within
introns of PCGs.
ł Overlapping transcripts (Fig.1D)-contain a
complete PCG within an intron on the same
strand.
Characteristic features:
ł Transcribed by RNA polymerase II
ł Polyadenylated
ł Spliced: 2.9 exons on average
ł Lower expression than PCGs
ł High tissue-specificity
ł Enriched in the chromatin
Functions. LncRNAs accomplish their role as gene regulators through a wide range of
mechanisms, as summarized in Fig 2, but the aim of this review is chromatin modification.
Different models have been proposed for chromatin modification mediated by lncRNAs (Fig.3)
according to the effect they have upon chromatin modifiers. LncRNAs may function as decoys
by sequestering chromatin modifiers, as guides by recruiting them to specific genome loci or
as scaffolds by bringing together different protein complexes.
Consisting with their essential role in gene control, some lncRNAs aberrations have been involved in the process of oncogenesis. Similarly to PCGs, these lncRNAs can be classified into 
tumor-suppressor lncRNAs or oncogenic lncRNAs according to their role in this process (2). 
Oncogenic lncRNAs Tumor-suppressor lncRNAs
ł Discovered as an antisense
transcript in the HOXC locus (3).
ł Represses transcription in trans in
the HOXD locus.
ł Functions as a scaffold recruiting
the PRC2 complex through its 5’
domain and the LSD1/CoREST/REST
complex through its 3’ domain.
ł Both the murine ortholog Pint and
the human PINT are regulated by
p53.
ł While Pint promotes proliferation
and survival, PINT inhibits them.
ł Pint is a trans-acting lncRNA which
regulates the expression of genes
downstream p53, mainly regulators of
apoptosis and cell cycle.
ł Identified in a germ-line deletion predisposing to melanoma (4).
ł Antisense to the tumor-suppressor gene p15 overlapping its two exons.
ł Gene silencing of p15, p16 and ARF.
ł Acts as a scaffold recruiting both PRC1 and PRC2.
ł Associated with acute myeloid and lymphoblastic leukemia, prostate cancer, neural
system tumors and melanoma.
CCND1 associated lncRNAs (6):
ANRIL(Antisense Noncoding RNA in the INK4 locus):
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PINT (P53-Induced Noncoding Transcript) (5):
Figure 1. Classification of lncRNAs based on
intersection with PCGs.
Figure 3. Models explaining lncRNA-mediated chromatin modification. Modified from (1).
Figure 2. Functions of
lncRNAs (red) within the
cell. They can regulate the
expression of PCGs (blue)
through chromatin modi-
fication [1] or transcription
regulation [2]. In addition,
antisense lncRNAs can pair
to specific sense RNAs to
modulate alternative
splicing [3] or to produce
endo-siRNAs [4]. They can
also form complexes with
proteins (purple) [5-7] or
function as small RNAs
precursors [8] or miRNA
sponges [9].
Figure 4. Guidance of PRC2 and LSD1 by HOTAIR (red).
ł Overexpressed associated with agressive metastatic phenotypes and poor survival in
breast, colorectal and hepatocellular carcinomas.
HOTAIR (HOX Antisense Intergenic RNA):
Figure 5. Guidance of 
PRC2 and PRC1 by
ANRIL (red).
ł Pint recruits PRC2 functioning as a guide.
ł PINT is a tumor-suppressor lncRNA downregulated in colorectal tumors.
Figure 6. Guidance of PRC2 by Pint (red).
Figure 7. TLS conformational change by CCND1 associated
lncRNAs (red).
ł Transcribed upstream the G1-phase
cyclin D1 (CCND1) promoter.
ł Function in cis repressing CCND1
expression.
ł Trigger a conformational change in
the TLS protein which allows it to
bind and repress the histone acetyl-
transferases CBP/p300.
ł Currently,  CCND1 associated  
lncRNAs have not been found
involved in any tumoral process.
